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NeuroinﬂammationEndogenous adenosine is a widely distributed upstream regulator of a broad spectrum of neurotransmitters,
receptors, and signaling pathways that converge to contribute to the expression of an array of important brain
functions. Over the past decade, the generation and characterization of genetic knockoutmodels for all four G-
protein coupled adenosine receptors, the A1 and A2A receptors in particular, has conﬁrmed and extended the
neuromodulatory and integrated role of adenosine receptors in the control of a broad spectrum of normal and
abnormal brain functions. After a brief introduction of the available adenosine receptor knockout models, this
review focuses on ﬁndings from the genetic knockout approach, placing particular emphasis on the most
recent ﬁndings. This review is organized into two sections to separately address (i) the role of adenosine
receptors in normal brain processes including neuroplasticity, sleep–wake cycle, motor function, cognition,
and emotion-related behaviors; and (ii) their role in the response to various pathologic insults to brain such as
ischemic stroke, neurodegeneration, or brain dysfunction/disorders. We largely limit our overview to the
prominent adenosine receptor subtypes in brain–the A1 and A2A receptors–for which numerous genetic
knockout studies on brain function are available. A1 and A2A receptor knockouts have provided signiﬁcant
new insights into adenosine's control of complex physiologic (e.g., cognition) and pathologic (e.g.,
neuroinﬂammation) phenomena. These ﬁndings extend and strengthen the support for A1 and A2A receptors
in brain as therapeutic targets in several neurologic and psychiatric diseases. However, they also emphasize
the importance of considering the disease context-dependent effect when developing adenosine receptor-
based therapeutic strategies. This article is part of a Special Issue entitled: “Adenosine Receptors”.osine Receptors”.
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1.1. Source and regulation of extracellular adenosine level
Adenosine is found in all cells where it is formed as a by-product of
purine nucleotide metabolism and other key metabolic cell processes
[1]. Beyond its role in energy-homeostasis, in the central nervous
system (CNS), adenosine also serves a neuromodulatory role where it
is capable of affecting neuronal excitability, release of various
neurotransmitters including glutamate, γ-aminobutyric acid
(GABA), acetylcholine, and dopamine, and synaptic plasticity [2].
Unlike neurotransmitters, however, adenosine is not stored and
released from vesicles but rather is generated by the highly regulated
intracellular metabolism of AMP (and transported out of the cell
through bi-directional facilitated diffusion transporters). Over the last
decade, it is increasingly recognized that the rapid (1 ms) extracel-
lular conversion of locally released adenine nucleotides like ATP and
also cAMP through a series of ectonucleotidases such as CD73 and
CD39 represents another important source of extracellular adenosine
in tissue [3–5]. Several processes operate in concert to maintain this
equilibrium in which extracellular adenosine levels are estimated to
fall within the 25–250 nanomolar range under basal conditions [4,6].
Antagonist studies have demonstrated that adenosine exerts a tonic
inhibitory effect on synaptic transmission, implying that under basal
conditions, adenosine levels are sufﬁcient to tonically activate
relevant adenosine receptor subtypes [1]. Under pathologic circum-
stances when cell function is compromised, however, extracellular
adenosine levels can rise as much as 100 fold, perhaps reaching a
concentration that activates the lower-afﬁnity adenosine receptor
subtypes, which then alters cellular function [7,8].1.2. Adenosine receptors (ARs)
1.2.1. Classiﬁcation of adenosine receptors
Adenosine receptors (ARs) are cell-surface receptors belonging to
the G-protein-coupled receptor family [9]. These receptors were
initially classiﬁed based on their pharmacologic response proﬁles to
agonism by adenosine analogues and antagonism bymethylxanthines
as determined by their ability to inhibit (i.e., A1 and A3 subtypes) or
stimulate (i.e., A2 subtype) adenylate cyclase (AC) [10,11]. The A2
receptor subtype was subsequently further categorized according to
the presence of high-afﬁnity (A2A) or low-afﬁnity (A2B) binding sites
for adenosine in brain [12]. However, similar afﬁnities for A2A or A2B
receptor stimulation of MAP kinase activity have also been reported in
cell culture studies [13]. To date, four AR subtypes have been
identiﬁed, puriﬁed, cloned, and expressed from mouse, rat, human,and other mammalian as well as non-mammalian species [9,14].
Successful molecular cloning and expression of these receptors have
not only deﬁnitively veriﬁed the presence of four different subtypes
but have also segued to genetic knockout and transgenic over-
expression studies to further elucidate the functions of each AR
subtype.
1.2.2. Expression, distribution, and signaling of adenosine receptors
1.2.2.1. A1 receptor (A1R). The A1R is the most highly conserved AR
subtype between species [9], and it probably exhibits the greatest
afﬁnity for adenosine compared to the other subtypes [15]. It is
expressed throughout the body with the highest levels observed in
brain, notably in neurons of cortex, hippocampus, and cerebellum, as
well as dorsal horn of spinal cord, eye, adrenal gland, and atria
[9,16,17]. The A1R is also expressed at intermediate levels elsewhere
in brain and in other peripheral tissues such as liver, kidney, white
adipose tissue, testis, and colon; it is most lowly expressed in lung
tissue [9]. In brain, A1Rs are found at both pre-synaptic and post-
synaptic sites [18]. A1R stimulation suppresses neuronal activity
through pre-synaptic and post-synaptic mechanisms by coupling
with Gi to inhibit the AC-cAMP-protein kinase A (PKA) signaling
pathway [11]. In striatum, A1Rs have also been shown to interact with
dopamine D1 receptors (D1Rs) on striatonigral medium spiny
neurons (MSNs) [19–21], providing yet another means by which
A1Rs can inﬂuence neuronal activity.
1.2.2.2. A2A receptor (A2AR). The A2AR also exhibits a high potency for
adenosine [15] and is widely expressed in different tissues, albeit at
varying levels. A2AR expression is highest in brain, spleen, thymus,
leukocytes, and blood platelets and intermediate in heart, lung, and
blood vessels [22,23]. Within brain, A2AR expression levels are highly
concentrated in dorsal and ventral striatum (on striatopallidal MSNs)
as well as in olfactory tubercle [24–29]. It is also recognized that
A2ARs are expressed at substantially lower levels outside of striatum
in brain regions including hippocampus and cortex [16,28]. In brain,
A2ARs are found predominantly at post-synaptic neurons in striatum,
but they are also detected at signiﬁcantly lower levels at pre-synaptic
sites in cortico-striatal terminals and in hippocampus [30]. Although
A2AR activation of the AC-cAMP-PKA pathway was originally
assumed to result from A2AR coupling to Gs [9], anatomic and
biochemical evidence later indicated that, at least in striatum, this
activation mainly occurs through coupling to Golf [31–33], and in
some cases, G-protein coupling may also require the βγ7 subunit
[34,35]. In addition to signaling via a PKA-dependent pathway, A2AR
signaling through a protein kinase C-dependent pathway in
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Furthermore, A2AR activation can trigger alternative signaling path-
ways via interaction with other receptors and signalingmolecules. For
instance, A2AR heterodimer and/or functional interactions with
A1Rs [38–40], dopamine D2 receptors (D2Rs) [41,42], group I
metabotropic glutamate 5 receptors (mGlu5Rs) [43,44], N-methyl-D-
aspartate receptors (NMDARs) [40,45], and cannabinoid CB1 recep-
tors (CB1Rs) [46,47] have been reported. A2ARs have also been noted
by in vitro assays and/or electrophysiology to affect signaling
through brain-derived neurotrophic factor (BDNF) in hippocampus
[48,49] and ﬁbroblast growth factor (FGF) as well as glial cell line-
derived neurotrophic factor in striatum [50] to modulate synaptic
transmission.
1.2.2.3. A2B receptor (A2BR). The A2BR possesses lower afﬁnity for
adenosine than does the A1R or A2AR subtype [51]. Regionally
deﬁning A2BR expression has largely been restricted to mRNA
evidence where A2BRs are thought to be broadly expressed but at
low levels [9]. Speciﬁcally, RT-PCR, Northern blot, and immunochem-
ical analyses have revealed higher expression in colon, cecum, and
bladder; intermediate expression in blood vessels, eye, and lung; and
lower expression in brain, adipose tissue, kidney, liver, ovary, adrenal
gland, and pituitary gland of rat [9,16,52]. No signiﬁcant level of A2BR
expression was detected in brain. Like A2ARs, A2BR signaling is
coupled to the Gs protein-AC-cAMP-PKA pathway. In addition, A2BRs
can couple with Gq/11 to activate phospholipase C [53,54], and some
evidence also suggests that they can interact with the arachidonic acid
pathway [55].
1.2.2.4. A3 receptor (A3R). The A3R was the last subtype to be
identiﬁed when it was ﬁrst isolated as an orphan receptor in rat testis
[56] and later cloned and expressed in other cell types [57]. Among
the AR subtypes, the A3R exhibits the greatest species variation in
expression pattern [9] and is notably insensitive to antagonism by
methylxanthine. Nonetheless, A3Rs are generally widely expressed in
the body in most species, and A3R transcript has been found in most
peripheral organs including testis, lung, liver, spleen, thyroid, kidney,
and heart [9,16,57] as well as in bone marrow-derived mast cells [58].
In brain, A3R expression levels are, at best, moderate in hippocampus
and cerebellum, and low elsewhere [9]. Within hippocampus, A3Rs
have been detected in neurons (i.e., CA1 pyramidal cells via single-cell
PCR analysis of mRNA) and their terminals (via western blot analysis)
[59]. A3Rs have also been detected in pial and intercerebral arteries
[60]. Like A1Rs, A3Rs can signal through coupling to Gi proteins to
inhibit AC activity and reduce intracellular cAMP concentrations
[57,61]. However, Gq protein activation of phospholipase C leading to
regulation of calcium status comprises the primary signaling pathway
utilized by these receptors [62–64].
1.2.3. Brain regional and cell type A1R and A2AR expression patterns
As noted in the previous section, A1Rs and A2ARs show a
complementary expression pattern in brain; that is, A1Rs are most
prominently expressed in hippocampus and cortex and only moder-
ately expressed in striatum while A2ARs are most abundantly
expressed in striatum and minimally expressed in hippocampus and
cortex. Moreover, within a speciﬁc tissue, ARs may show varying sub-
regional and cellular expression patterns. For example, in striatum,
A1Rs are localized to post-synaptic striatonigral MSNs of the direct
pathway [19] whereas A2ARs are localized to post-synaptic striato-
pallidal MSNs of the indirect pathway [26]. At the sub-cellular level,
A1Rs are highly expressed at pre-synaptic terminals [65] while A2ARs
are predominantly expressed at post-synaptic sites in striatum
[30,66]. This anatomic segregation is functionally signiﬁcant and is
relevant for understanding the role of these receptors in motor
control, Parkinson's disease (PD), and L-dopa-induced dyskinesia as
well as the therapeutic potential of A2AR antagonists for the motorsymptoms of PD [41,66,67]. Interestingly, A2ARs appear to localize
mainly to asymmetric, excitatory striatal synapses (expressing
VGLUT) [68] where pre-synaptic A2ARs were shown to co-localize
with A1Rs to ﬁne-tune glutamate release [38]. These synapses were
recently identiﬁed to largely comprise glutamatergic cortical afferents
onto direct pathway striatonigral MSNs [69]. The functional signiﬁ-
cance of A2ARs' ﬁne-tuning of glutamatergic neurotransmission in
striatum from pre-synaptic or post-synaptic locations are likely highly
relevant for A2AR-dependent effects on physiologic and pathologic
states. These implications have been thoroughly discussed in a recent
review by Schiffmann and colleagues [70].
In summary, the presence of various AR subtypes in distinct brain
regions, sub-regions, cell types, and synaptic sites provides an array of
paths by which adenosine can differentially modulate brain functions.
Such diversity also points to an important strategy for targeted
therapeutic interventions. On the other hand, this complexity makes
characterization of adenosine and AR functions in brain more difﬁcult.
The development of genetic engineering strategies has facilitated the
dissection of these functions and highlighted potential pathways in
the CNS.
2. Genetic adenosine receptor animal models relevant to
understanding adenosine and adenosine receptor modulation of
brain function
Transgenic and knockout animal models represent highly valuable
tools to assess protein functions in vivo [71,72]. Earlier pharmacologic
strategies are intrinsically limited by their partial speciﬁcity or
selectivity. Moreover, AR ligands often exhibit poor solubility, and
systemic injection of these ligands showed variable CNS penetration
and had the potential to produce non-speciﬁc effects. Thus, the use of
a pharmacologic strategy alone to elucidate AR function in brain was
less than ideal. Genetic strategies have helped circumvent many of
these limitations. Through genetic engineering, AR gene knockout by
the targeted deletion of a critical AR exon, or transgenic over-
expression of the AR gene, has been achieved in rodents (mostly
mouse). Furthermore, the conditional knockout of some AR genes has
been attained using the Cre-loxP system. This strategy places the
expression of Cre recombinase (and thus AR gene deletion) under the
control of a region/tissue- or cell type-speciﬁc promoter. Such a
strategy allows for the localization of AR functions to particular brain
regions or cell types. Moreover, depending on the promoter, a degree
of temporal speciﬁcity can be attained, with most gene deletions
restricted to the early postnatal period. These advantages therefore
render conditional knockout a particularly useful strategy to address
AR functions in brain. Today, knockout mouse models have been
generated for each of the four AR subtypes, and several brain region-
speciﬁc as well as cell type-speciﬁc AR knockout mice are available
(see overview below in section 2.1). These genetic strategies have
substantially advanced the adenosine and AR ﬁeld, extending ﬁndings
from pharmacologic studies and revealing novel and important
physiologic functions of the different receptor subtypes.
2.1. A1 receptor transgenic models
2.1.1. Global A1R knockout mice
Two constitutive, global A1R knockout mouse lines (gb-A1R KO)
from similar mixed genetic backgrounds, 129sv/C57BL/6J [73] or 129/
OlaHsd/C57BL [74], have been generated. Gb-A1R KO mice in both
lines were viable, without gross anatomic abnormalities, develop-
mentally normal, and fertile. Body weight measured up to six months
of age, heart rate, and blood pressure were all unaffected by gb-A1R
KO in both lines, and normal body temperature was also reported in
one line [74]. Subsequent studies in these knockout lines, however,
reported that male gb-A1R KO mice produced fewer pups and
exhibited sub-optimal spermatozoa capacitation [75]. These mice
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be attributable to accelerated aging processes and the accumulation of
cardiovascular, hepatic, and renal dysfunction over time [76].
2.1.2. Brain-speciﬁc conditional A1R knockout mice
Brain-speciﬁc conditional A1R knockout mice (mixed 129SvJ-
C57BL/6 genetic background) were recently generated [77] using the
Cre/loxP strategy in which cre transgene expression was placed under
the control of a CaMKII-α promoter to provide both regional and
temporal speciﬁcity of Cre expression and thus A1R gene knockout
[78]. Successful A1R deletion was reported throughout most of the
brain but most notably in cortex and hindbrain and to a lesser extent
in thalamus by X-gal staining, mRNA autoradiography, and mRNA
quantiﬁcation.
2.1.3. Adeno-associated virus (AAV)-mediated brain region-speciﬁc A1R
knockout
Focal deletion of A1Rs in hippocampal CA1 or CA3 neurons has
been attained by local injection of AAV vectors containing the cre
transgene construct into the brains of micewith a critical exon ﬂanked
by loxP sites [79]. This strategy allowed for a temporal and regional
speciﬁcity that has helped to distinguish the functional roles of pre-
synaptic versus post-synaptic A1Rs.
2.2. A2A receptor transgenic models
2.2.1. Global A2AR knockout mice
Four constitutive, global A2AR knockout mouse lines (gb-A2AR KO)
from different genetic backgrounds, CD1 [80], mixed Sv-129-C57BL/6,
Sv-129 [81] or C57BL/6 [82,83], have also been generated. Gb-A2AR KO
mice from all four lines were viable, without gross anatomic
abnormalities, and fertile. However, increased body weight, heart
rate, blood pressure, platelet aggregation, as well as striatal D1R and
D2R expression were only reported in gb-A2AR KO mice from a CD1
background [80,84], thus emphasizing the importance of considering
the inﬂuence of genetic background on phenotypic analyses of
knockout mouse lines. Given the constitutive deletion of A2ARs in
gb-A2AR KOmice and A2AR interactions with dopaminergic pathways,
it is important to note that, at least in two different gb-A2AR KO lines,
striatal dopamine receptor levels as well as tyrosine hydroxylase (TH)
immunoreactivity and dopamine transporter (DAT) function were
indistinguishable between gb-A2AR KO and wildtype control mice
from one group [85].
2.2.2. Forebrain- or striatum-speciﬁc conditional A2AR knockout mice
Brain-regional deletion of A2ARs has now been achieved in the
forebrain (i.e., striatum, cortex, hippocampus) [86] or striatum [87]
only. A2AR KO mice derived from both conditional knockout mouse
lines were viable, without gross anatomic abnormalities, and fertile.
Compensatory changes in A1R, D1R, or D2R expression levels in
striatum and cortex as well as tyrosine hydroxlase immunoreactiv-
ity were also absent in both knockout mouse lines (Wei et al.,
unpublished data). Forebrain-speciﬁc A2AR KO mice (fb-A2AR KO;
now near congenic C57 BL/6 genetic background) were generated
using the Cre/loxP strategy in which cre transgene expression was
placed under the control of the forebrain neuron-speciﬁc CaMKII-α
promoter [86]. The postnatal deletion of A2ARs circumvents
potential developmental effects of constitutive A2AR gene deletion.
Striatum-speciﬁc A2AR KO mice (st-A2AR KO; mixed 129-Steel-
C57BL/6-FVB genetic background) were later generated using the
same Cre/loxP strategy but with cre transgene expression driven
instead by the embryonic striatal neuron-speciﬁc Dlx5/6 promoter
elements [87]. Neuron-speciﬁc deletion in both conditional A2AR
KO mouse lines was conﬁrmed by PCR analysis of brain cells sorted
by ﬂow cytometry [87].2.2.3. Transgenic over-expression of A2AR in rat brain
Transgenic rats over-expressing human A2ARs under the control
of the neuron-speciﬁc enolase promoter have also been generated
[88]. The transgene was mainly expressed in neurons of the cortex,
hippocampus, cerebellum, and striatum. Transgenic mice were
reported to express lower levels of D2Rs and mGlu5Rs only in
striatum; A1R and D1R expression levels were unchanged in striatum
and cortex.
2.3. A2B receptor transgenic models
Constitutive, global A2BR knockout mice (A2BR KO) of an 80%
C57BL/6J genetic background have recently been developed [89].
These mice were viable, without gross anatomic features, and
normotensive. Mice lacking the A2BR, however, exhibited higher
basal levels of pro-inﬂammatory cytokines (e.g., TNF-alpha, Il-6)
and an up-regulation of several vascular adhesion molecules (e.g.,
E-selectin, P-selectin, ICAM-1), differences that were augmented
upon challenge. These ﬁndings suggest an important anti-inﬂam-
matory role for A2BRs, and the presence of baseline phenotypes
highlights that, at least in some tissues, basal adenosine levels are
sufﬁcient to activate A2BRs to produce an effect, despite adenosine's
low afﬁnity for the receptor. Also of note, the use of a receptor
knockout/reporter gene knock-in strategy permitted the visualiza-
tion of A2BR expression throughout the body and revealed regional-
and cell type-speciﬁc A2BR expression, which would be unattainable
by other less sensitive detection methods. To our knowledge, A2BR
KO mouse studies on brain function have not yet been reported.
2.4. A3 receptor transgenic models
Constitutive, global A3R knockout mice (A3R KO) of a mixed B6D2
and C57BL/6 genetic background have been generated [58]. These
mice are reported to be viable, fertile, developmentally normal,
lacking gross anatomic defects, and free from compensatory changes
in the expression of the other AR subtypes [58]. In addition, body
weight, heart rate, and blood pressure were indistinguishable
between these A3R KOmice and their wildtype controls. Interestingly,
A3R KO reduced intraocular pressure, thus highlighting the potential
for targeting A3Rs to treat glaucoma [90]. Although global over-
expression of A3Rs led to embryonic lethality [90], successful A3R
over-expression was achieved in heart [91]. Several pharmacologic
studies have examined A3R function and/or its role in hypoxia-
ischemiamodels [e.g., 92, 93, 94], but some evidence suggests that the
A3R agonist CI-IBMECA used in these studies also activates A1Rs
[59,94,95]. Thus, the partial selectivity of this and other A3R ligands
limits one from concluding that any effect is strictly an A3R-mediated
effect. With the development of targeted A3R KO mouse models, its
various CNS functions are now beginning to be validated and/or newly
revealed [96,97].
2.5. Double receptor knockout mice and genetic models targeting
adenosine metabolism or transport
Additional genetic models are available to study adenosine and AR
function but will not be discussed in this review. Several double
knockout mice to study A2AR interactions with other receptors
including A1Rs [98], D2Rs [99], and CB1Rs [100] have been generated.
In addition, several models have targeted important regulators of
adenosine metabolism (e.g., adenosine kinase (ADK), adenosine
deaminase (ADA), CD73, and CD39) and transport (e.g., equilibrative
nucleoside transporter type 1 (ENT1)) [101–106]. Transgenic mice
with reduced brain adenosine tone due to over-expression of ADK
(under the control of the human ubiquitin promoter), ENT1 knockout
mice [103,107–109], CD73 knockout mice [110], and CD39 knockout
mice [111] have been described and provide an important snapshot of
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pathologic conditions [112,113]. While ADA knockout mice surviving
to adulthood are now available and show increased adenosine levels
in most tissue types including brain [114], we are unaware of any
reported phenotypes in these mice that conﬁrm ADA's impact on
brain processes, as might be expected given the neurologic abnor-
malities observed in ADA-deﬁcient patients [115,116]. This knowl-
edge gap is presumably because their assessment would largely be
hindered/confounded by the marked immunologic phenotypes
resulting from ADA deﬁciency.
3. Knockout models to study adenosine receptor function in
physiologic and pathologic conditions in the central nervous
system
Since the 1970s, when research on the neuromodulatory functions
of adenosine ﬁrst took ﬂight, adenosine has been noted to inﬂuence
numerous critical brain functions under both physiologic and
pathologic conditions. The following two sections will focus on
ﬁndings from the above mentioned genetic AR knockout models, with
particular emphasis on the most recent ﬁndings, to separately address
(i) the role of ARs on normal brain processes and (ii) their role in
response to various pathologic insults to brain such as ischemic
stroke, neurodegeneration, or brain dysfunction/disorders. We largely
limit our overview to the prominent AR subtypes in brain–the A1R
and A2AR–for which numerous genetic knockout studies on brain
function are available. The lower expressed A2BR and A3R subtypes
will only be brieﬂy touched upon in this review due to limited genetic
knockout studies on brain functions. A review of adenosine's
peripheral actions can be found elsewhere [82,117–120]. Earlier
reviews have also provided a nice overview of pharmacologic studies
addressing the role of these receptors on brain function
[2,4,14,41,65,121–125].
3.1. Brain adenosine receptor functions revealed by knockout mouse
models
3.1.1. Sleep–wake physiology
An important role for adenosine as an endogenous sleep factor is
supported by several lines of experimental evidence [126,127].
Extracellular adenosine levels in the basal forebrain increase during
prolongedwakefulness and decrease during sleep [128]; however, the
source of extracellular adenosine during the sleep–wake cycle is not
clear. Using a transgenic mouse line expressing dominant-negative
SNARE to suppress gliotransmission [129], Hallass et al. demonstrated
that the reduction in glial cell-derived extracellular adenosine was
associated with an accumulation of sleep pressure and cognitive
impairment from sleep deprivation. This provides direct evidence that
adenosine released from astrocytes modulates the accumulation of
sleep pressure and its cognitive sequelae [130].
Adenosine exerts its effect on the sleep–wake cycle by acting at
ARs. Both A1Rs and A2ARs contribute to adenosine-mediated
modulation of the sleep–wake cycle [131,132]. A large body of
pharmacologic studies suggests that endogenous adenosine acts at
A1Rs in basal forebrain to modulate the sleep–wake cycle [126].
Consistent with this notion, brain-speciﬁc conditional A1R KO mice
showed selective attenuation of slow wave activity (SWA) rebound
and a widespread, synchronized neuronal activity that varied directly
with previous waking duration [77]. Consequently, these mice also
exhibited impaired working memory [130], which suggests that
extracellular adenosine acting at A1Rs is required for normal rebound
SWA and downstream working memory functions.
On the other hand, evidence for A2AR involvement in sleep–wake
physiology largely stems from studies examining the arousal effects of
the non-selective AR antagonist caffeine. Recent pharmacologic as
well as genetic knockout studies suggest an important role for A2ARsin mediating this effect. For example, caffeine-induced arousal was
largely intact in gb-A1R KO mice but essentially abolished in gb-A2AR
KOmice [133]. The contribution of A2ARs to caffeine's arousal effect is
consistent with recent studies showing that a genetic variant of the
A2AR gene (ADORA2A) in humans is associated with individual
sensitivity to caffeine's effect on sleep [134]. Furthermore, striatum-
speciﬁc deletion of A2ARs, like global deletion, was found to blunt this
caffeine-mediated arousal effect (Shen et al., unpublished data). This
raises an intriguing possibility that caffeine's arousal effects are
mediated by A2ARs in striatal neurons, a brain region traditionally
associated with motor and motivational behavior.
3.1.2. Motor function
AR knockout mouse models have permitted conﬁrmation that
A2ARs are themain effectors of adenosine-basedmodulation of motor
activity, isolation of the motor-enhancing effects of A2AR antagonists
to A2ARs on striatal post-synaptic neurons, attribution of caffeine's
motor stimulant effects largely to A2AR blockade (at least at lower
doses), and identiﬁcation of D2R-independent functionally signiﬁcant
motor outcomes of A2ARs.
3.1.2.1. Spontaneous activity. Since A2ARs are highly expressed on
indirect pathway MSNs throughout striatum, a brain region critically
involved in motor control, these striatal neuronal A2ARs were largely
presumed to function as the main effectors of adenosine-based
modulation of motor activity and thus the molecular targets of A2AR
antagonist-induced motor stimulation. The recent demonstration of
absent A2AR antagonist-induced motor stimulation in st-A2AR KO
mice provided the ﬁrst deﬁnitive evidence that post-synaptic striatal
neuronal A2ARs are required for themotor stimulating effects of A2AR
antagonists such as KW-6002 [87]. This effect was previously shown
to depend only partially on D2Rs, thus revealing that A2ARs can
facilitate striatal neuronal activity to produce outcomes that are
independent of their antagonistic interaction with D2Rs [99].
Interestingly, while A2AR antagonists are well-known to induce
motor stimulation, genetic A2ARKOhas failed toproduce a similar effect
on basal motor activity. Instead, adult gb-A2AR KOmice (from different
genetic backgrounds) consistently exhibited reduced spontaneous
activity compared to their wildtype controls [80,81,85,135,136], an
effect that was more pronounced during the dark phase [85] and not
related to accelerated habituation [80,85], general motor impairment
assessed by the accelerating rotarod [85,137], or abnormal circadian
rhythm [85]. At least in one line, this phenotype might be explained by
heightened anxiety-like behavior [80] and reduced dopaminergic
tone [84]. On the other hand, differences in basal activity levels were
not reported for fb-A2AR KO or st-A2AR KO mice harboring brain
region- and neuron-speciﬁc deletions of the A2AR [86,87,138]. This
difference between gb-A2AR KO and conditional A2AR KOs suggests
that the phenotype observed in gb-A2AR KOmicemight also stem from
non-speciﬁc or adaptive effects of constitutive global gene deletion, or
alternatively,may also reﬂect the activity of A2ARs at non-neuronal (i.e.,
astrocytic or microglial) sites. Conﬁrmation of the latter awaits the
development of A2AR KO restricted to these non-neuronal cell types.
Nonetheless, the clear discrepancy between genetic (i.e., reduced or no
effect on activity) and pharmacologic (i.e., enhanced activity) studies
may relate to partial blockade and/or acute/short-term blockade of
A2ARs by selective antagonists compared to complete absence and/or
long-term depletion of the receptor in these knockout models.
Unlike gb-A2AR KOmice, gb-A1R KO produced minimal impact on
spontaneous motor activity [74,76,98,136]. Moreover, gb-A1R KO
failed to affect motor coordination but was accompanied by a
reduction in muscle strength [76]. Recently, it was shown that A1R-
A2AR double KO mice exhibited reduced peak spontaneous activity
relative to A1R KO, A2AR KO, and wildtype controls [136]. This further
suggests that while A2ARs appear to be most important AR subtype in
effecting adenosine's modulation of spontaneous motor activity, A1Rs
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which A2ARs are still present) but only uncovered when A2ARs are
also eliminated. Lastly, A3R KO mice were also reported to exhibit
reduced spontaneous activity that was restricted to the dark phase of
the light-dark cycle [96,139] and more pronounced among the female
mice [139]. This effect of A3R KO was postulated to relate to a
potential role for A3Rs in the control of arousal since responses to
caffeine and amphetamine were also impaired in these mice [96]. No
evidence was found to indicate that the A2BR is involved in
modulating motor activity [136].
3.1.2.2. Psychomotor activity by caffeine. Caffeine is a widely consumed
psychoactive substance that is also a non-selective AR antagonist. The
use of AR KO mice has also helped to elucidate the molecular
mechanisms of caffeine's motor stimulant effects. This topic has been
covered in detail in a recent review [140]. Brieﬂy, studies in gb-A2AR
KO mice conﬁrmed the A2AR dependence of this effect
[80,81,98,136,141], which was further attributed to A2ARs on
forebrain neurons [138]. However, these studies also suggest that
caffeine has other targets because gb-A2AR KO does not result in
complete abolishment of caffeine's stimulatory effect and is without
effect at higher doses of caffeine [135,141]. It appears, however, that
caffeine can have A2AR- and A1R-independent effects on motor
activity since gb-A1R KO mice also did not reliably differ from their
wildtype controls when administered caffeine at a high dose
[135,136]. It is possible still that these A2AR- and A1R-dependent
effects at higher doses of caffeine may result from effects on A3R
function since A3R KO mice showed attenuated responses to caffeine
[96] at a dose (15 mg/kg, i.p.) that failed to produce, in other studies, a
difference in gb-A2AR KO or gb-A1R KOmice relative to their wildtype
controls.
3.1.2.3. Psychomotor activity by dopamine agonists and NMDAR
blockade. Dopaminergic and glutamatergic function in striatum are
posited to underlie psychomotor effects [142]. Adenosine and its
receptor targets are known to modulate dopaminergic and glutama-
tergic signaling in striatum, and ARs, namely A2ARs, have been shown
by knockout studies to modulate psychomotor effects produced by
various drugs such as cocaine, amphetamine, and phencyclidine.
Evidence from A2AR knockout studies paints a general picture of
reduced psychomotor stimulation by the dopaminergic compounds
cocaine and amphetamine and by the NMDAR antagonist phencycli-
dine. Gb-A2AR KO mice (from different genetic backgrounds)
exhibited a selective attenuation in the motor response to cocaine
or amphetamine without any effect on D1R or D2R direct agonist-
induced motor stimulation or suppression, respectively [85]. In
keeping with these results, fb-A2AR KO mice also displayed a
reduction in their motor responses to cocaine [87] or amphetamine
[86]. These KO mice also showed an attenuated hyperlocomotor
response to phencyclidine [87]. Thus, stimulation of A2ARs on
forebrain neurons appears to be important for the full expression of
hyperlocomotor responses to cocaine, amphetamine, and
phencyclidine.
In contrast, A2AR deletion restricted to post-synaptic striatal
neurons in st-A2AR KO mice enhanced rather than attenuated the
hyperlocomotor response to a single injection of cocaine or phency-
clidine [87]. These results indicate that striatopallidal A2ARs predom-
inantly inhibit psychomotor activity and are consistent with the
A2AR-D2R antagonistic interaction at striatopallidal MSNs [41]. Thus,
the enhanced psychomotor response in st-A2AR KO mice is likely
attributable to increased striatopallidal D2R activity. Most impor-
tantly, comparative analysis of the psychomotor response proﬁle to
cocaine or phencyclidine in fb-A2AR KO and st-A2AR KO mice
revealed for the ﬁrst time, a critical role for the previously under-
recognized extra-striatal A2ARs in modulating psychomotor activity
[87]. The opposite behavioral phenotypes observed in fb-A2AR KOmice (i.e., attenuation) and st-A2AR KO mice (i.e., enhancement)
following cocaine or phencyclidine treatment suggested that the
excitatory effect of extra-striatal A2ARs predominates and counters
the inhibitory effect of striatopallidal A2ARs on psychomotor activity.
This idea was further substantiated by combining pharmacologic and
genetic knockout strategies. Speciﬁcally, the impact of extra-striatal
A2AR blockade on cocaine-induced psychomotor activity was
assessed by administering KW-6002 to st-A2AR KO mice. These
mice, like fb-A2AR KO mice, showed attenuated cocaine-induced
psychomotor activity. This effect of extra-striatal A2ARs was specu-
lated to result from pre-synaptic A2AR modulation of glutamate
release at cortico-striatal nerve terminals.
Lastly, the A3R has recently been demonstrated to affect
amphetamine-induced hyperactivity [96]. Notably, global loss of
A3Rs attenuated the response to amphetamine.
3.1.3. Neuronal synaptic plasticity
Synaptic plasticity is often inferred by examining long-term
potentiation (LTP) and long-term depression (LTD), phenomena
which have been documented in brain regions such as hippocampus
and striatum and which are generally thought to form the molecular
and cellular basis of associated learning and memory processes [143–
145]. Several of these processes involve neurotransmitters like
glutamate and dopamine and their receptor targets (e.g., NMDARs,
D1Rs). Adenosine acting at ARs is well known to modulate the release
of multiple neurotransmitters, including glutamate and dopamine, in
brain regions relevant for cognition including hippocampus and
striatum [40]. Several lines of evidence suggest that ARs participate in
modulating different forms of plasticity.
3.1.3.1. A1 receptor modulation of synaptic plasticity. In hippocampus,
purines such as adenosine, ATP, and cAMP were shown to negatively
modulate glutamatergic transmission via an A1R-dependent mecha-
nism since both selective A1R antagonism and A1R KO eliminated this
inhibitory effect of adenosine [74,146]. In the Schaffer-collateral CA3-
CA1 pathway, NMDAR-dependent LTP elicited by either tetanic
stimulation or theta-burst as well as CA1 LTD were unaffected by
A1R KO [147], thus suggesting that A1Rs do not crucially participate in
CA3–CA1 hippocampal post-synaptic plasticity. These A1R KO mice
did, however, exhibit impaired (nearly absent) paired pulse facilita-
tion, which is consistent with a pre-synaptic locus of short-term
plasticity control by A1Rs at this synapse. This set of outcomes in A1R
KO mice is in stark contrast to abundant pharmacologic evidence
using A1R agonists and antagonists that supports the hypothesis that
endogenous adenosine can stimulate A1Rs to modify excitatory
synaptic transmission in terms of pre-synaptic glutamate release or
post-synaptic NMDAR responses [1,4,148–150] and attenuate several
measures of synaptic plasticity including LTP, LTD, and depotentiation
in the CA1 region of hippocampus in vitro [151–155]. At hippocampal
mossy ﬁber synapses, basal pre-synaptic A1R activation by endoge-
nous adenosine was suggested to underlie activity-dependent
synaptic plasticity through tonic suppression of basal release
probability [156]. Removal of the adenosine tonus by pre-treatment
with the A1R antagonist DPCPX, genetic A1R knockout, or enzymatic
degradation by ADA selectively augmented mossy ﬁber basal
transmission [156]. Importantly, these manipulations individually
attenuated in vitro measures of both short-term plasticity (e.g.,
frequency facilitation and paired pulse facilitation) and LTP (a
NMDAR-independent process) at this synapse, effects that could be
bypassed by bath application of a GABA agonist [156]. That A1R
inactivation depresses frequency facilitation at this synapse was
recently replicated in vivo in freely moving rats [157]. It has been
suggested that some of these depressant effects of adenosine on
mossy ﬁber synaptic transmission may involve pre-synaptic A1R
stimulation and the direct inhibition of pre-synaptic calcium channels
[158]. The generally opposite effects of A1R inactivation on mossy
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from differences in the nature of plasticity at these synapses; i.e., pre-
synaptic NMDAR-independent versus post-synaptic NMDAR-depen-
dent, respectively [156]. In contrast to the above ﬁndings, however,
the magnitude of frequency facilitation, paired-pulse facilitation, or
post-tetanic potentiation at mossy ﬁber synapses was unaffected by
A1R knockout or A1R antagonism in another in vitro study [159]. This
led the authors to conclude that the basal release probability likely
does not require local adenosine or the critical control of A1R
activation at mossy ﬁber synapses. These discrepancies were, in part,
attributed to some differences in experimental conditions, and
additional studies are required to clarify this issue.
In striatum, evidence in cortico-striatal brain slice preparations
from gb-A1R KOmice suggests that A1Rs may predominantly mediate
adenosine's modulation of NMDAR-triggered LTD: A1R gene deletion
nulliﬁed fEPSP/PS depression elicited by application of either NMDA
or adenosine [160]. This result in gb-A1R KOmice is inconsistent with
an earlier pharmacologic study which reported that induction of
short-term depression but not LTD at these synapses was blocked by
A1R antagonism and triggered by A1R agonism [161]. Thus, the nature
of A1R modulation on LTD or other forms of striatal plasticity remains
unclear.
The discrepancy between pharmacologic and genetic A1R manip-
ulation in hippocampus and striatum may be partly due to
compensatory developmental effects in gb-A1R KO mice and partly
due to the complex action of A1Rs in different cellular (e.g., neuronal
versus non-neuronal) or subcellular (e.g., pre-synaptic versus post-
synaptic) elements and brain regions, all with potentially different
effects. Therefore, A1R's modulation of synaptic plasticity in hippo-
campus and striatum is likely complex and may depend on the local
milieu and which subset of A1Rs is activated to guide its outcome; i.e.,
enhancement or attenuation of synaptic plasticity.
3.1.3.2. A2A receptor modulation of synaptic plasticity. A critical role for
A2ARs in a unique form of post-synaptic NMDAR-dependent LTP but
not pre-synaptic plasticity at hippocampal mossy ﬁber synapses has
been recently demonstrated at the pharmacologic level [162].
Intriguingly, a recent pharmacologic study recording activity in live,
behaving mice demonstrated the inhibitory impact of A2AR blockade
on the fEPSP slope at the CA3-CA1 synapse and the conditioned
response behaviors in a trace eyeblink conditioning paradigm [163].
These in vivo measures were conﬁrmed in the same study in which
experimentally evoked LTP was also reported to be abolished by the
selective A2AR antagonist SCH58261. Some additional pharmacologic
evidence suggests that A2AR stimulation, at least in the Schaffer-
collateral pathway, may augment BDNF-induced LTP in hippocampus
[48]. Indeed, the only known study examining hippocampal LTP in
A2AR KO mice conﬁrmed this effect by demonstrating a loss of BDNF-
induced LTP and reduced BDNF levels in hippocampus of gb-A2AR KO
mice and that of wildtype mice treated with the selective A2AR
antagonist ZM241385 [49]. This study suggested that tonic activation
of A2ARs is required for maintaining normal levels of BDNF tone in
hippocampus and for facilitating BDNF-induced LTP at this synapse.
Interestingly, recent evidence using A2AR ligands suggests that A2AR
activation in hippocampus may also potentiate BDNF-induced
responses including CA3-CA1 LTP through recruitment of TrkB
receptors to lipid rafts [164].
In addition to affecting hippocampal long-term plasticity, several
studies using slices obtained from gb-A2AR KO mice suggest that
A2ARs are capable of modulating cortico-striatal plasticity. Speciﬁ-
cally, the induction of LTP but neither the basal synaptic transmission
nor the paired-pulse facilitation index of pre-synaptic function at
cortico-accumbal synapses was attenuated in gb-A2AR KO mice
compared to wildtype control mice [165]. This phenotypic proﬁle was
recapitulated by treatment with either an A2AR antagonist or a
speciﬁc PKA inhibitor, thereby suggesting that the A2AR-dependentLTP process occurs through a PKA-dependent pathway. This ﬁnding
agrees with a recent report that LTP at glutamatergic synapses onto
striatopallidal MSNs requires A2AR activation since pharmacologic
A2AR blockade abolished spike timing-dependent LTP in this neuronal
population [166]. Furthermore, dominant-negative A2AR mutant
constructs as well as pharmacologic manipulations in BAC transgenic
mice to tag D1R-expressing direct and D2R-expressing indirect
pathway MSNs led to the proposal that A2ARs and FGF receptors
synergize to facilitate a NMDAR-dependent cortico-striatal LTP in
striatopallidal MSNs through activation of MEK1/2 and subsequent
ERK1/2 phosphorylation [50]. To date, we are unaware of any genetic
A2AR knockout studies speciﬁcally examining LTD in striatum,
although A2AR agonismwas reported to produce at best, inconsistent
effects on cortico-striatal short-term depression and LTD [161].
Interestingly, A2ARs interact with both D2Rs and CB1Rs, which are
regarded as important mediators of striatal LTD [47,167–169]. It
would be interesting to examine cortico-striatal LTP and LTD in the
recently developed st-A2AR KO mice and the concomitant impact of
D2R or CB1R pathway manipulations.
3.1.3.3. A3 receptor modulation of synaptic plasticity. Some pharmaco-
logic work suggests that A3Rs may modulate synaptic plasticity in the
CNS. A selective A3R agonist was shown to only exert effects on
synaptic transmission through antagonizing A1R-mediated inhibition
of excitatory neurotransmission at hippocampal Schaffer-collateral
CA3-CA1 synapses [170], an effect that may result from the partial
speciﬁcity of the drug which evidence suggests can bind to native
A1Rs [59,94,95]; no direct effects of A3R stimulation on CA1 EPSPs,
paired pulse facilitation, or LTP were reported [94,170]. On the other
hand, pharmacologic A3R stimulation alone selectively increased
theta-burst LTP [94] and blocked pre-synaptic mGlu5R inhibitory
effects on fEPSPs [171] at hippocampal CA3-CA1 synapses as well as
blocked EPSPs in pyramidal cells of rat frontal cortex [92]. These
effects were blocked by treatment with a selective A3R antagonist.
That A3R antagonism alone had no effect suggests that at least under
normal physiologic conditions, endogenous adenosine is not acting at
A3Rs to signiﬁcantly affect synaptic plasticity in these brain regions. In
contrast, another study showed that A3R agonism could not modify
hippocampal synaptic transmission either alone or through effects on
A1R-mediated functions [59]. The functional signiﬁcance of A3Rs in
the CNS, particularly on neuronal plasticity, however, has been largely
unexplored using A3R KO mice. Recently, the induction of hippocam-
pal Schaffer-collateral CA3-CA1 LTP [97] or EPSC depression [172] by
the chemokine CX3CL1 was shown to be prevented in A3R KO mice.
Therefore, the function of A3Rs in modulating synaptic plasticity
remains muddy and may or may not involve A1Rs in hippocampus.
3.1.4. Cognition
The notion that adenosine potentially modulates cognition
probably arises from the general belief that consumption of caffeine,
the most widely used psychoactive compound, improves cognitive
performance in humans. Evidence for a strictly pro-cognitive effect of
caffeine, however, is inconsistent and may reﬂect caffeine's impact on
other processes such as arousal, attention, and mood (e.g., during
withdrawal), which can in turn inﬂuence performance on cognitive
tasks [173]. Recent work in transgenic mice possessing low adenosine
tone in the brain due to over-expression of adenosine kinase (ADK)
demonstrated profound deﬁcits in spatial reference and working
memory and in cued fear conditioning [113], thus providing strong
genetic evidence that adenosine regulates cognition under physio-
logic conditions. These behavioral phenotypes were also accompanied
by perturbations in their response to dopaminergic and glutamatergic
compounds, suggesting that adenosine-mediatedmodulation of these
respective pathways contributes to its cognitive proﬁle.
As discussed in the previous section, adenosine actsmainly at A1Rs
and A2ARs to modulate neurotransmitter systems, neuronal
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relevant for learning and memory. The precise contribution of A1Rs
and A2ARs to adenosine's regulation of cognitive functions, however,
remains to be established. Traditionally, A1Rs were largely thought to
execute adenosine's potential modulatory effects on cognition
because of its relative abundance in regions classically studied in
learning and memory like hippocampus. Studies in AR knockout mice
in the realm of cognition are only beginning to reveal the complexities
and vastness of adenosine's functions in brain. The importance of
A2ARs for some forms of learning and memory is now gradually
reaching the forefront. The following sections provide an overview of
the impact of genetic manipulation of ARs on learning and memory
performance, emotional regulation, and sensorimotor processing.
Only by considering all these cognitive phenotypes together can one
gain a balanced and more accurate insight into ARs' modulation of
cognition.
3.1.4.1. Learning and memory performance. Earlier work, largely using
antagonists and agonists, has suggested a role for adenosine and its
receptor targets in learning andmemory, but these ﬁndings have been
inconsistent. It is possible that this diverse array of ﬁndings reﬂects
the different contributions of the different AR subtypes in distinct
brain regions, all of which are more difﬁcult to precisely target using
only pharmacologic tools or even a global AR KO strategy. The current
set of brain region-speciﬁc AR KO mice provide the ﬁrst set of tools to
begin dissecting the contribution of the different AR subtypes in
different brain regions on several types of learning and memory
processes. In addition to probable differences in brain regional
contributions by different AR subtypes, these apparent inconsisten-
cies may also likely reﬂect differences in the timing of the
pharmacologic manipulation across studies, a factor that the currently
available brain region-speciﬁc AR KO models cannot adequately
address. Alternative strategies such as inducible/reversible, condi-
tional AR knockout or expression models or well-timed and locally
delivered selective pharmacologic and/or genetic agents would be
required to provide greater temporal (i.e., within a timescale more
suitable for learning and memory testing) and regional speciﬁcity of
AR inactivation. Lastly, differences in the behavioral tasks and
cognitive domains examined, both of which are generally restricted
in number and scope, may also contribute to the apparent
discrepancies. Therefore, a comprehensive and systematic assessment
of the impact of each AR subtype in each relevant brain region (e.g.,
hippocampus, cortex, striatum) on the multiple phases of learning
and memory (e.g., encoding, storage, consolidation, retrieval) using
different behavioral tasks to evaluate distinct cognitive domains is
necessary to adequately dissect the nature of AR-modulation of
learning and memory. This is a formidable endeavor that now seems
to be underway and gaining momentum.
3.1.4.1.1. A1 receptors in learning and memory. Evidence in A1R KO
mice suggests that A1Rsmay not play as critical a role as once believed
in mediating some of the mnemonic effects of adenosine. Of note,
global deletion of the A1R failed to produce any performance effect in
the water maze in three separate experiments from two different
knockout mouse lines [76,147,174]. In these studies, gb-A1R KO mice
showed normal acquisition and retention of a spatial reference
memory, normal spatial working memory, and normal ability to
learn the new position of a ﬁxed platform during reversal learning.
These ﬁndings in gb-A1R KOmice suggest that the A1R receptor is not
critical for the expression of normal spatial reference memory or
working memory under physiologic conditions. However, old gb-A1R
KO mice (19 months old) were reported to show spatial working
memory deﬁcits in the 6-arm radial tunnel maze [147], a ﬁnding that
was consistent with that from an earlier pharmacologic study
showing that hippocampal A1Rs inﬂuence working memory [175].
This earlier ﬁnding, however, was attributed to reduced test
environment habituation rather than to a mnemonic process [147].Interestingly, in disease models, A1R stimulation has been shown to
prevent scopolamine-induced working memory deﬁcits [176] while
A1R blockade has been shown to prevent morphine-induced
impairment in the retrieval of a spatial reference memory [177].
These ﬁndings suggest that A1Rs may gain relevance under certain
pathologic conditions. It should be noted that these studies in gb-A1R
KO mice were all on the background of potentially confounding
alterations of emotional processing/behaviors; these changes will be
reviewed in the next section (see section 3.1.4.2).
3.1.4.1.2. A2A receptors in learning and memory. A growing body of
evidence now suggests that A2ARs may play an important role in
adenosine's modulation of learning and memory. Transgenic and
knockout studies have recently provided some of the direct evidence
that A2ARs are major players in adenosine's control of working
memory. For example, gb-A2AR KO mice showed improved spatial
recognition memory in an elevated Y-maze, but this effect might
instead be explained by maze hypoactivity [178]. We recently also
showed that similar deletion of A2ARs (on a different genetic
background) selectively enhanced working memory performance in
both the spatial water maze and radial arm maze [179]. Importantly,
these effects were unaccompanied by changes in spatial reference
memory performance or activity assessed by swim speed in the water
maze and distance traveled in the radial arm maze. A2AR-dependent
modulation of working memory is also consistent with the ﬁnding
that transgenic rats over-expressing A2ARs in brain exhibited
impaired working memory in several behavioral paradigms including
the water maze, 6-arm radial tunnel maze, and novel object
recognition tasks [88]. These phenotypes were also selective, with
spatial reference memory, motor function, and anxiety-like behavior
left intact. Sinceworkingmemory is typically thought to require intact
cortical as well as striatal function, these ﬁndings in rodents with
global changes in A2AR gene expression illuminate the possibility that
A2ARs in cortex, despite their relative low expression in brain, can
produce functionally signiﬁcant outcomes on learning and memory.
This notion is supported by our recent conditional knockout mice
study showing that striatal and extra-striatal (i.e., cortical and/or
hippocampal) A2ARs exert opposite effects on motor stimulation
induced by cocaine or phencyclidine [87], which suggests that extra-
striatal and not striatal A2ARs direct the principal outcome of A2AR
stimulation. To obtain a broader understanding of A2AR modulation
of learning andmemory, the role of A2ARs should be explored in brain
region-speciﬁc A2AR knockout mice.
A2ARs in striatum, namely those on post-synaptic striatal neurons,
have also been recently demonstrated to critically modulate learning
andmemory and notably habit formation [180]. In this study, st-A2AR
KOmicewere trained in an instrumental learning task to learn to lever
press at a stable level that in wildtype mice had become habitual.
While st-A2AR KO mice successfully learned to lever press, their
behavior remained sensitive (i.e., more goal-directed/ﬂexible) to both
devaluation and reversal/omission procedures, as evidenced by the st-
A2AR KO mice readily reducing their lever presses. These results
suggest that st-A2AR KO mice exhibited weaker habit formation
compared to wildtype mice, a result that is consistent with impaired
cortico-striatal LTP in gb-A2AR KO mice [165]. Thus, this targeted
knockout approach allowed for the identiﬁcation of a novel role for
A2ARs in habit formation and further localized their effect to
striatopallidal pathway neurons. The mechanism behind this pheno-
type might relate to A2AR interactions in striatum with the
dopaminergic or endocannabinoid systems, which are both linked
to habit learning [181,182] and capable of affecting striatal plasticity
[145]. In light of this phenotype in st-A2AR KO mice and the
observation that working memory is enhanced in gb-A2AR KO mice,
weaker habit learning in the face of deﬁcient striatal A2AR activity
may in fact partially explain a greater ﬂexibility in response patterns,
or vice versa. Additional studies will be necessary to elucidate these
possibilities.
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notion that suppression of A2AR activity is pro-cognitive and raise the
possibility that the A2AR may represent a target for improving
cognitive function under normal and pathologic conditions, as ﬁrst
suggested by Cunha and Agostinho [183]. That A2AR blockade
reverses memory impairment caused by various brain insults from
aging [184], beta-amyloid deposition [185,186], or spontaneous
hypertension [187] is encouraging and suggests that the A2AR
antagonists may present a therapeutic strategy for ameliorating
memory dysfunction under these pathologic conditions.
3.1.4.1.3. A3 receptors in learning and memory. Studies of A3R
modulation of learning and memory in knockout mice have not yet
been reported. However, the A3R agonist IB-MECA was reported to
reduce scopolamine-induced deﬁcits in spontaneous alternation in
the Y-maze and in passive avoidance via an A1R-independent
mechanism [188]. Given the impact of A3R KO on cytokine-elicited
electrophysiologic changes in hippocampus, it will be interesting to
see whether hippocampal-dependent task performance is altered in
A3R KO mice, particularly in disease models.
3.1.4.1.4. Summary. Studies using AR knockouts have provided
some clariﬁcation of the potential impact of A1Rs and suggest an
important role for A2AR signaling on some types of learning and
memory. Nonetheless, additional studies are needed to examine other
forms of learning and memory and to provide brain regional
speciﬁcation as well as temporal dissection of each AR's functions.
3.1.4.2. Emotional and sensorimotor regulation. Adenosine is thought to
modulate anxiety, exploration, aggressive behaviors, depressive
responses, and sensorimotor gating. The following sections provide
an overview of the impact of AR knockout on these behaviors.
Adenosine's impact on anxiety has recently been thoroughly reviewed
and thus will only brieﬂy be discussed here [189].
3.1.4.2.1. Anxiety. The anxiogenic effects of caffeine are largely
attributed to A1R antagonism [190]. Indeed, studies in A1R KO mice
have generally revealed consistent phenotypes that are suggestive of
augmented emotional reactivity. For example, gb-A1R KO mice have
been shown to exhibit more anxiety-like behaviors in a variety of
tasks including the elevated plus maze, light-dark test, novel open
ﬁeld, emergence test, and o-maze [74,76,174]. These mice were also
reported to exhibit emotional instability as reﬂected by increasedwall
hugging behavior in response to reversal in a water maze task [174].
Yet, it remains unclear whether these mild anxiogenic phenotypes
reﬂect changes in arousal since gb-A1R KO mice also exhibited
reduced habituation to more familiar environments [98,147].
The possibility that the A2AR, another target of caffeine, might
modulate anxiety and related behaviors is supported by a positive
correlation between the acute anxiogenic effects of caffeine and
speciﬁc A2AR gene polymorphisms in humans [191] and the
observation that the A2AR gene may be linked to panic disorder
[192]. However, unlike A1Rs, the role of A2ARs in modulating anxiety-
like states in transgenic animal studies is less consistent. While mice
on a CD1 background with global A2AR deletion were initially
reported to respond more to anxiogenic stimuli [80], basal anxiety-
like behavior did not differ between A2AR KO and wild-type mice in
another study [193], although the A2AR KO mice in the latter study
were reported to exhibit greater sensitivity to the anxiolytic effect of
ethanol. This lack of consistency might be explained by potential
compensation in mice globally lacking the A2AR. Indeed, it has been
shown in gb-A2AR KO mice on a CD1 background that purinergic
utilization, as determined by the density of nucleoside transporters
and A1Rs, is altered in brain regions like hippocampus or hypothal-
amus that are relevant for anxiety and arousal [194].
These changes in adenosine levels in this gb-A2AR KO mouse line
might also affect anxiety through actions at A3Rs. Nevertheless,
although A3R KO mice showed some evidence of an anxiety
phenotype on the elevated plus maze and light-dark box, theseﬁndings were largely attributed to the hyperactive phenotype which
was noted in the novel open ﬁeld, elevated plus maze, and light-dark
box [195].
3.1.4.2.2. Aggression. Adenosine may also impact aggressive
behaviors. This has been observed in both global A1R and A2AR KO
mouse lines, with knockout mice showing more aggression than their
wildtype controls in a resident-intruder test [74,80]. It is also possible
that these aggressive phenotypes may simply reﬂect anxiety status.
3.1.4.2.3. Depression. Adenosine's potential role in depressive
behaviors, as in anxiety-like phenomena, stems largely from clinical
studies in which patients with major depression were found to have
reduced serum ADA activity (thus increasing adenosine tone), which
was inversely correlated with disease severity [196]. Both selective
A2AR antagonists as well as global A2AR deletion have been shown to
reverse signs of behavioral despair in the tail suspension and forced
swim tests independently of its hyperlocomotor effect [197].
However, A2AR and A1R antagonists were also shown to reverse
adenosine's anti-depressant effects while A2AR and A1R agonists
mimicked adenosine's actions [198]. On the other hand, A3R KO mice
exhibited heightened signs of behavioral despair, spending more time
immobilized in both the tail suspension and forced swim tests [195].
3.1.4.2.4. Sensorimotor processing. A2ARs are most abundantly
expressed in striatum, including nucleus accumbens, which is a critical
locus for prepulse inhibition (PPI), a measure of sensorimotor gating
function [199]. A2ARs might therefore be expected to contribute to PPI
expression. Indeed, pharmacologic evidence has shown that A2ARs in
nucleus accumbens are important modulators of PPI [200], and A2AR
agonists can reverse the apomorphine-induced PPI deﬁcit [201]. Inmice
where A2ARs were globally deleted, startle amplitude, startle habitu-
ation, and prepulse inhibition of the acoustic startle response were
reduced [202]. It shouldbenoted, however, that interpretation of thePPI
deﬁcit here may be confounded by a baseline difference in startle
response among gb-A2AR KO and wildtype mice [203]. To our
knowledge, PPI has not yet been examined in A1R or A3R KO mice.
3.1.4.2.5. Summary. In summary, the contributions of the AR
subtypes to different types of learning and memory are gradually
being unveiled. Studies in A2AR KO mice, in particular, have largely
focused on typical striatum-dependent learning processes, where
A2ARs are most highly concentrated. These studies have revealed
novel roles for A2ARs, likely in striatum, in the control of associative
learning (instrumental learning in particular), working memory, and
habit learning. The inﬂuence of A1Rs on these cognitive domains is less
clear. It appears that A1Rs may play a greater role in the regulation of
emotional expression and processing. Collectively, the ﬁndings from
these studies emphasize the importance of broadly studying the
phenotypes in AR KOmice when characterizing KOmice. These studies
raise the exciting possibility that A2ARs may represent a target for
improving cognitive function under physiologic or pathologic states.
3.2. Adenosine receptor function in disorders of the central nervous
system
3.2.1. Neuroprotection
Adenosine acting primarily at A1Rs is generally believed to protect
brain tissue against multiple types of brain insults including ischemia,
hypoxia, excitotoxicity, trauma, and neurodegenerative disease. On
the other hand, recent evidence also suggests that adenosine acting
primarily at A2ARsmay contribute to neurotoxicity, neuronal damage,
and cell death. The following sections describe recent ﬁndings on the
neuroprotective effects of ARs in different brain injury models in an
attempt to reveal the therapeutic potential of AR agents in these
pathologic conditions.
3.2.1.1. Ischemia and hypoxia
3.2.1.1.1. A1 receptor role in ischemia and hypoxia. Adenosine
stimulation of A1Rs is well known to exert an inhibitory effect on
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glutamate release. A1Rs have therefore been hypothesized to protect
against neuronal damage in the face of ischemia or hypoxia or similar
pathologic conditions characterized by supra-physiologic elevations
of adenosine levels in brain. Although multiple studies using
pharmacologic strategies have largely supported this neuroprotective
beneﬁt of A1R stimulation, studies in gb-A1R KOmice have conﬁrmed
this conclusion only in certain experimental paradigms.
The ﬁrst conﬁrmation of this neuroprotective hypothesis in gb-
A1R KO mice examined responses to hypoxia induced by carbon
monoxide. Compared to hippocampal slices fromwildtypemice, slices
from gb-A1R KO mice showed a markedly reduced and delayed
protective response to hypoxia, as determined by measuring the
expected dampening of fEPSPs and thus glutamatergic neurotrans-
mission [74]. Moreover, whereas slices from wildtype mice fully
recovered functionality (i.e., restoration of fEPSP responses) upon re-
oxygenation of the medium, slices from gb-A1R KOmice displayed no
such improvement, thus suggesting that the lack of A1Rs during
hypoxia contributed to signiﬁcant and lasting hippocampal neuronal
impairment. The attenuation but incomplete abolishment of the
response to hypoxia in gb-A1R KO mice also suggests that while A1Rs
are important and critical in this pathologic process, other mecha-
nisms regulating hypoxia's effects on neuronal damage are likely also
involved. Nonetheless, additional work examining hypoxic damage in
primary astrocytes prepared from gb-A1R KO and wildtype mice
supports the original study with evidence of greater cytotoxicity
observed in astrocytes from gb-A1R KO mice [204]. This ﬁnding is
interesting because it suggests that A1Rs on non-neuronal cells might
contribute to the potential neuroprotective effects of A1R stimulation.
On the other hand, A1Rs have also been demonstrated in genetic
knockout models to have no effect on the level of ischemia/hypoxia-
induced damage. For example, the level of brain damage induced by
global ischemia was indistinguishable between gb-A1R KO and
wildtype mice [205]; a similar result was also obtained from gb-A1R
KO and wildtype hippocampal slices placed under in vitro ischemic
conditions [205]. However, consistent with a neuroprotective role for
A1R stimulation, wildtype mice pretreated with a selective A1R
antagonist prior to the ischemic insult showed marked exacerbation
of neuronal damage [205]. These data highlight the potential
differences in outcomes generated by pharmacologic versus genetic
models, and they suggest that some of A1Rs effects, at least in regard
to hypoxia-induced neuroprotection, may be compensated for.
In immature brain, pharmacologic A1R stimulation has been
shown to exacerbate rather than attenuate ischemic injury [206].
Consistent with this surprising result, genetic deletion of A1Rs
revealed neuroprotective effects in immature gb-A1R KO mice raised
under hypoxic conditions; these mice were indistinguishable from
wildtype mice raised under normoxic (i.e., room air) conditions when
using assessments of ventriculomegaly and white matter loss as
endpoints [207]. Interestingly, such hypoxia-induced changes were
also reduced in A1R+/− mice. This strongly suggests that even a
partial reduction in A1R activity provided some protection against
hypoxia-induced injury and raises the possibility that A1R antago-
nism, even if incomplete, may still represent a useful strategy for
treating hypoxia-based injuries during development. These “surpris-
ing” results of exacerbation of damage by pharmacologic A1R
stimulation and neuroprotection by genetic A1R knockout in
immature brain may also reﬂect the phenomenon of “effect
inversion", which has been reported for the A1R in ischemia/hypoxia
animal models [208]. That is, the impact of pharmacologic A1R
manipulation will largely depend on the timing of the manipulation
relative to the insult, where chronic versus acute drug administration
can produce opposite effects.While acute A1R agonism or chronic A1R
antagonism can be neuroprotective, chronic A1R agonism or acute
A1R antagonism can exacerbate ischemic injury [208]. In contrast to
inactivation by A1R ligands, constitutive gb-A1R KO produces apersistent inactivation of the receptor. Therefore, the neuroprotective
effect of gb-A1R KO in this particular study, whichwas not observed in
the pharmacologic studies showing a different outcome, may relate to
the chronicity of the A1R deletion and the timing of the insult.
From this brief overview, compared to the generally believed
protective role of A1Rs, which is supported by studies using pharma-
cologic tools, evidence from genetic A1R deletion studies using
knockout mouse models only partially conﬁrm the potential for A1R
activation as a neuroprotective strategy—a neuroprotective effect of
A1Rs is only observed in certain experimental paradigms, and in other
paradigms, a relatively complex and contradictory role for A1Rs in
neuroprotection is revealed. Speciﬁcally, studies in A1R KO mice have
demonstrated protection, no protection, or exacerbation of damage in
ischemia/hypoxia models of brain injury. This may partly reﬂect the
different role of A1Rs in various stages of development. Depending on
the particular brain injurymodel used, aswell as the age of the animal at
the time of insult, it appears that A1Rs may produce a variable effect
when it comes to neuroprotection following brain ischemia and/or
hypoxia. Possible compensatory mechanisms in knockout animals may
also mask the consequences of A1R deﬁciency or loss. Additional
research will need to conscientiously control for various factors and
dissect out the contributions of each before A1Rs can be brought to the
clinic as a pharmacotherapeutic strategy.
3.2.1.1.2. A2A receptor role in ischemia and hypoxia. A2ARs, like
A1Rs, have also been shownbymultiple studies to assume an important
role in animal models of focal and global ischemia. In fact, due to the
relatively reduced potential for peripheral side effects, A2ARs have been
considered a more attractive target for therapeutic exploration. Several
pharmacologic studies using ﬁrst generation A2AR antagonists have
demonstrated that A2AR blockade confers neuroprotection in animal
models of brain ischemia [209–211]. Evidence from gb-A2AR KO mice
has overcome the concern of potential non-speciﬁc effects inherent to
pharmacologic approaches, and it strongly supports that A2ARblockade
might confer neuroprotection against brain damage induced by
transient focal ischemia [81]. Speciﬁcally, gb-A2AR KO signiﬁcantly
reduced the brain damage and functional neurologic sequelae produced
by transientmiddle cerebral artery occlusion (MCAO). However, similar
to observations from A1R studies, the effect of A2AR blockade on
neuroprotection against ischemia/hypoxia when examined in imma-
ture animals differed from that observed in adult animals. Using a
cerebral hypoxia ischemia model in seven-day-old mice, for instance,
gb-A2AR KO was found to exacerbate brain injury and produce
impairments in several behavioral indices of motor function [137].
This “surprising” result suggested that A2AR stimulation, not blockade,
might also play a protective role under the circumstance of neonatal
ischemic/hypoxic brain injury. Therefore, when studying and interpret-
ing the potential neuroprotective effects of ARs, one should consider the
developmental stage of the animal (e.g., brain slices and primary cell
cultures derived from early developmental stages).
Since A2ARs are not only expressed at high levels in neurons, but
are also highly expressed in inﬂammatory cells and glial cells, the
possibility that A2ARs on inﬂammatory cells contribute to adenosine's
action in brain injury was subsequently explored. The nature of
A2AR's involvement in neuroprotection after ischemia/hypoxia was
examined using a chimeric mouse model in which A2ARs on bone
marrow-derived cells (BMDCs) were selectively inactivated or
reconstituted by bone marrow transplantation [212]. This procedure
permitted the isolation of A2AR's effects to this particular cell type.
Selective deletion of A2ARs in BMDCs captured the neuroprotective
effect observed in gb-A2AR KO mice while selective reconstitution of
A2ARs in BMDCs reinstated the brain damage. Thus, A2ARs on BMDCs
also contribute to neuroprotection against ischemic/hypoxic insult,
and targeting A2AR blockade to these cell types might offer an
effective therapeutic strategy against ischemic brain injury.
3.2.1.1.3. A3 receptor role in ischemia and hypoxia. Despite the low
expression of A3Rs in the CNS, several studies have attempted to gain
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function of A3Rs was ﬁrst demonstrated using mice with genetic
deletion of the A3R [195]. Although all mice exhibited histologic and
morphologic changes in hippocampus following repeated bouts of
hypoxia (induced by carbon monoxide), A3R KO mice displayed a
more pronounced loss of CA2-3 hippocampal pyramidal neurons. This
effect of A3R KO was mimicked by the repeated administration of an
A3R-selective antagonist to wildtype mice and was also accompanied
by deﬁcient hippocampal-dependent contextual fear conditioning.
These data suggest that A3R agonists might afford protection against
hypoxia-induced neuronal damage. Consistent with this, A3R KOmice
were shown in another study to also exacerbate cerebral infarction
induced by MCAO, and wildtype but not A3R KO mice beneﬁted from
pre-treatment with an A3R selective agonist [213]. The mechanism of
A3R agonist-induced neuroprotective effects in hypoxia is unclear but
may involve the suppression of apoptosis [213] or may involve non-
neuronal targets. The latter possibility is supported by recent evidence
that glial cells engineered to lack the A3R were more sensitive to
hypoxia than were wildtype cells [204]. These data also pointed to a
cytoprotective role of adenosine that is mediated by both A1Rs and
A3Rs in primary mouse astrocytes. Collectively, these data highlight
the neuroprotective potential of A3R agonists.
3.2.1.2. Parkinson's disease (PD). The high abundance of A2ARs in
striatopallidal neurons, coupled with its ability to interact antagonisti-
cally with D2Rs and its motor improving effects, has led to the proposal
thatA2ARs represent a non-dopaminergic target for PD treatment [214–
217]. In recent years, epidemiologic and complimentary animal studies
have provided evidence that raised the exciting possibility that A2AR
blockade might present the additional beneﬁt as a neuroprotective
strategy to sloworhalt dopaminergic neuronaldegeneration [216–219].
As result, the A2AR is emerging as a leading, non-dopaminergic drug for
the treatment of PD, and several A2AR antagonists have entered and
completed clinical phase II and III trials for advanced PD patients, thus
conﬁrming their motor beneﬁts [220–224]. These developments have
been expertly reviewed recently [216,217,219,222,225]. Therefore, we
only provide a brief overview of the genetic A2AR knockout studies
in animal models of PD.
Studies using genetic A2AR knockout models have contributed to
this exciting development by demonstrating the A2AR antagonists
exert dual beneﬁts through several distinct mechanisms—A2AR
antagonists act at striatopallidal neurons to enhance motor activity
and probably act through other mechanisms to exert their neuropro-
tective effect against dopaminergic neurodegeneration [138]. By
selectively deleting A2ARs in forebrain neurons [138], or more
selectively, in striatal neurons [87], our studies provide deﬁnitive
evidence that A2AR antagonists act at striatal neurons to enhance
motor activity. These ﬁndings not only conﬁrm the early pharmaco-
logic [226,227] and genetic studies, but also localize this therapeutic
effect of A2AR antagonists to striatal neurons. Furthermore, A2AR
knockout work has provided important evidence supporting the
neuroprotective property of A2AR antagonists in animal models of PD
and has also provided a neurobiological basis for the inverse
relationship between human caffeine consumption and reduced PD
risk [228,229]. Using gb-A2AR KO mice, we showed that A2AR loss
conferred protection in the 1-methyl-4-phenyl-1,2,3,6-tetrahydro-
pyridine (MPTP) model of PD [218]. The neuroprotective effect of
A2AR inactivation was also observed in PD models induced by the
toxin 6-hydroxydopamine (6-OHDA) and more recently by trans-
genic expression of alpha-synuclein (Schwarzschild et al., SFN abs.
2009).
Despite the consistent demonstration of neuroprotection by A2AR
inactivation, the mechanism by which A2AR inactivation protects
dopaminergic neurons is still largely unknown. Until recently,
perhaps one of the main obstacles has been the uncertainty and
scarcity of direct evidence regardingwhether A2ARs are expressed atappreciable levels in dopaminergic neurons (early studies failed to
detect A2AR expression in these neurons), despite several functional
studies showing that A2AR agonists and antagonists could modify
dopamine release in striatum [230,231]. Recently, A2AR-immuno-
reactivity in TH- or DAT-immunopositive dopaminergic terminals in
striatum was demonstrated in puriﬁed nerve terminal preparations
[232], thereby providing a potential direct mechanism by which
A2ARs can impact the survival of dopaminergic neurons in PD
models.
In recent years, the contribution of A2ARs in different brain regions
and cell types has been speciﬁcally examined. Recently, we showed
that selectively inactivating forebrain neuronal A2ARs was not
sufﬁcient to confer neuroprotection against acute MPTP exposure,
despite being able to eliminate the motor stimulant effects of the
selective A2AR antagonist KW-6002 [138]. Only when A2AR antago-
nists were delivered via intracerebroventricular injection to fb-A2AR
KO mice could a neuroprotective effect be observed in these mice
[138]. This observation strongly suggested that A2AR antagonists act
at non-forebrain neurons to exert a neuroprotective effect. However, a
recent study using the same fb-A2AR KOmouse line showed complete
prevention of dopamine neuron degeneration and gliosis in substantia
nigra pars compacta and partial prevention of gliosis in striatum
following sub-chronic MPTP administration [233]. The divergent
observations derived from the same fb-A2AR KO mouse line in these
two studies are likely the result of differences in the experimental
paradigm such as the duration of MPTP toxin exposure (i.e., acute
versus subchronic). The impact of differentMPTP paradigms, however,
still needs further assessment.
In addition to their potential neuroprotective beneﬁts, A2AR
antagonists may possess anti-tremor and anti-dyskinesic properties.
Indeed, A2AR antagonists have recently shown promise as an
alternative non-dopaminergic PD therapeutic drug [214,234]. We
limit our discussion here to the potential anti-dyskinesic effects since,
to our knowledge, A2AR's impact on animal models of PD tremor has
only been examined using pharmacologic tools [235–238]. Although
pharmacologic dopamine replacement with L-dopa remains the
mainstay drug treatment for PD [239,240], up to 75% of patients will
develop disruptive dyskinesias, coined L-dopa-induced dyskinesia
(LID), within ten years of starting L-dopa therapy [241]. While several
studies suggest a role for A2ARs in the development and maintenance
of LID, the ability of A2AR antagonists to modify LID remains unclear:
co-administration of KW-6002 with L-dopa failed to alter LID in rats
[242] and non-human primates [243,244], and more importantly,
clinical data now suggest that KW-6002 may slightly increase
dyskinesia [220,221,223,224,245]. While some discrepancies may
relate to the dose of L-dopa used (since KW-6002 may permit the use
of a lower and therefore less dyskinesogenic dose of L-dopa [220]),
they might also be partially explained by different effects of A2ARs in
distinct relevant brain regions or cellular elements.
Recent AR knockout studies have now begun the process of
dissecting out their contribution to LID. In the 6-OHDA PD model, gb-
A2AR KO or fb-A2AR KO mice exhibited attenuated contralateral
rotational sensitization to repeated L-dopa treatment [246–248], an
effect that was paralleled by reduced abnormal involuntary move-
ments (AIMS measure of LID) and striatal preproenkaphalin mRNA
[247,248]. A similar phenotypic proﬁle was observed in A1R KO mice
but not in A1R-A2AR double knockout mice [248]. These ﬁndings in
multiple genetic knockout mouse lines collectively suggest that
blockade of either A2ARs (likely in forebrain neurons) or A1Rs may
prevent or reduce LID. The mechanism behind this effect nonetheless
remains elusive: while blockade of A2ARs on post-synaptic striato-
pallidal neurons accounts for the motor stimulant effect of A2AR
antagonists, this cannot account for the observed anti-dyskinesic
effect in gb-A2AR KO or fb-A2AR KO mice. Additional studies, which
further break down the contribution of A2ARs in different brain
regions and cellular elements, will be necessary. Moreover, whether
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demonstrated by A2AR antagonists still requires further investigation.
3.2.1.3. Huntington's disease (HD). The enrichment of A2ARs to
striatum and the cellular localization of these receptors to striato-
pallidal neurons (the most susceptible neurons undergoing neurode-
generation in HD) indicated that A2ARs might also contribute to the
pathologic processes underlying HD [225,249]. This possibility is
supported by the observation that A2AR expression is reduced in HD
patients [250]. Several studies have now examined the consequences
of pharmacologic and/or genetic A2AR inactivation on striatal damage
produced by the mitochondrial complex II inhibitor 3-nitropropionic
acid (3-NP), a toxinmodel for HD, and in R6/2mice, a geneticmodel of
HD. Evidence from pharmacologic studies showed that both A2AR
agonists and antagonists were capable of producing neuroprotection
in HD models. For example, ﬁve-week repeated treatment with the
A2AR agonist CGS21680 at postnatal week seven was shown to
prevent striatal atrophy, ventricular enlargement, and HTT aggrega-
tions in R6/2 mice [251]. In agreement, A2AR activation in cultured
cells protected against HTT-induced neuronal cell death through a
cAMP-PKA pathway [252]. On the other hand, the A2AR antagonist
SCH58261 has also been shown to reduce behavioral abnormalities
and neurochemical changes in R6/2 mice [253,254]. In a recent study,
A2AR inactivation by chronic administration of SCH58261 signiﬁ-
cantly increased the number of nNOS-immunoreactive striatal
neurons in R6/2 mice, thus also suggesting a protective effect of
A2AR antagonism in the HD model [255]. In agreement with this
notion, 3-NP-induced striatal damage was attenuated by treatment
with A2AR antagonists [256]. This dichotomous proﬁle might reﬂect
the opposite effects of A2ARs located at pre-synaptic (exacerbating
role due to stimulatory effects on glutamate release) versus post-
synaptic (protective role) striatal sites as well as the striatal sub-
region affected [257].
Similar to pharmacologic studies, A2AR KO mouse models have
also yielded a complex picture of A2AR modulation of striatal
neuronal death in HD. Knockout mice lacking A2ARs everywhere
were reported to either attenuate or exacerbate striatal damage
depending on the dose of 3-NP insult [257]. Another study, however,
reported exacerbation of 3-NP striatal damage as well as neurologic
deﬁcits in gb-A2AR KO mice but not in fb-A2AR KO mice [83]. This
exacerbatory phenotype was attributed to A2ARs on BMDCs since
transplantation of bone marrow cells derived from gb-A2AR KO mice
towildtypemice recapitulated the level of striatal damage observed in
gb-A2AR KO alone following 3-NP insult. Together, these ﬁndings in
genetic and pharmacologic models indicate that the effect of A2ARs in
HD is also complex, both at the synaptic and cellular levels. Further
investigation is needed before A2AR-targeted strategies can be used
to treat HD patients.
3.2.1.4. Traumatic brain injury (TBI). Extracellular adenosine increases
rapidly and dramatically during traumatic brain injury (TBI) and may
modulate the cascade of secondary damaging effects including
excitotoxicity and inﬂammation triggered by TBI. Recent studies
have evaluated the effects of A2ARs on TBI using an A2AR KO model.
Global deletion of A2ARs was found to protect against acute cortical
impact injury as assessed by brain water content, histology, cell death,
and neurological deﬁcit scores [258]. These effects were associated
with a suppression of glutamate and inﬂammatory cytokine levels. A
later study extended these ﬁndings by using selective inactivation of
A2ARs on BMDCs to demonstrate that A2AR loss on either BMDCs or
non-BMDCs was sufﬁcient to confer protection against TBI [259].
These studies suggest that control of TBI by A2ARs can occur at
multiple cellular targets and via multiple cellular mechanisms.
Interestingly, using this same paradigm, A2ARs were found capable
of producing dichotomous effects on TBI responses and outcomes in a
manner that depended on local glutamate concentrations [260].Notably, when glutamate levels were low, A2AR agonists attenuated
the morphologic, behavioral, cellular, and cytokine changes induced
by TBI. In contrast, when glutamate levels were high (as is typically
the case following TBI), A2AR antagonists (not agonists) were found
to produce a similar protective outcome. These ﬁndings collectively
raise the prospect that A2AR antagonism may represent a potential
therapeutic strategy for TBI. More importantly, they bring attention to
the need to consider local glutamate levels when determining the
appropriate administration of select A2AR-based pharmacologic
compounds following TBI.
3.2.1.5. Summary. Evidence from ischemia/hypoxia, PD, HD, and TBI all
point to a potential role for adenosine, A1Rs, and A2ARs in their
pathologic processes in terms of neuroprotection. Overall, genetic
knockout models have conﬁrmed the neuroprotective effect afforded
by A1R activation and A2AR inactivation against various brain insults.
However, the results from these lines of work also reveal that the
effect of A1Rs and A2ARs on brain injury is highly context-dependent
—the outcome of adenosine modulation of brain injury may depend
on the mode of brain insult (e.g., acute versus sub-chronic), distinct
cellular elements, chronologic age, extracellular glutamate concen-
tration, and/or the different time points in which the outcomes are
evaluated.
3.2.2. Neuroinﬂammation
Neuroinﬂammatory reactions participate in a wide range of acute
and chronic neurodegenerative disorders. Adenosine is thought to
critically contribute to inﬂammation and tissue damage [261], and
recently, evidence has accumulated to suggest that ARs partake in
brain inﬂammatory processes and might serve important therapeutic
targets for treating diseases of the brain in which inﬂammation plays a
key role in its etiology or progression [262]. However, as observed in
studies examining AR function in neuroprotection, the inﬂuence of
ARs on neuroinﬂammatory processes is also perplexing: pharmaco-
logic studies have reported an anti-inﬂammatory outcome following
either stimulation or blockade of ARs [225]. Although all four AR
subtypes have been implicated in neuroinﬂammation to date [225],
the neuroinﬂammatory impact of ARs has up to now only been
examined in A1R and A2AR genetic knockout models, with the
majority of these studies focusing largely on the role of the A2AR
subtype. Therefore, we provide here an overview of the role of ARs in
neuroinﬂammation as revealed by studies using A1R or A2AR KO
mice.
3.2.2.1. A1 receptor role in neuroinﬂammation. Studies of neuroin-
ﬂammation in gb-A1R KOmice suggest that A1R blockade exacerbates
damage induced by experimental allergic encephalomyelitis (EAE)
model and TBI. Firstly, gb-A1R KO mice were reported to develop a
severe progressive-relapsing form of EAE [263]. This was character-
ized by more pronounced demyelination and axonal injury as well as
greater microglial/macrophage activation in these knockout mice
compared to wildtype controls. Further analysis in macrophages
obtained from gb-A1R KO mice revealed increased pro-inﬂammatory
gene expression. Moreover, signiﬁcant oligodendrocyte cytotoxicity
was observed upon exposure to soluble factors derived from these
perturbed macrophages. These data strongly suggest that A1Rs on
macrophages contribute to neuroinﬂammation and related cell death.
Interestingly, A1R expression was down-regulated in the microglia of
wildtype mice showing neuroinﬂammation in the EAE model, and
caffeine reduced EAE severity, an effect that was accompanied by up-
regulation of microglial A1Rs. Since EAE is a model for multiple
sclerosis, it has been suggested that A1Rs could be targeted to limit
the demyelination characteristic of this disease [263]. Secondly, a
neuroinﬂammatory role for A1Rs has also recently been demonstrated
in a cortical TBI model. In this study, the microglial response, notably
Iba-1+ microglial cells, was markedly enhanced in several brain
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thalamus of gb-A1R KO mice compared to wildtype mice [264]. Along
with the demonstration that A1R stimulation inhibits microglial
proliferation, these results support the notion that activation of A1Rs
reduces TBI-induced neuroinﬂammation, likely by suppressing the
microglial proliferative response. Collectively, these two gb-A1R KO
studies using two different methods of damage and inﬂammation
induction strongly indicate that A1Rs serve an anti-inﬂammatory
function in brain and suggest that modulation of microglial activity
can be therapeutic.
3.2.2.2. A2A receptor role in neuroinﬂammation. Evidence for AR
modulation of neuroinﬂammation has largely focused on the A2AR
subtype. Several studies using A2AR KOmice generally seem to suggest
that the brain inﬂammatory response and/or resultant damage from
different injurymodels (e.g., ischemia/hypoxia, TBI,MPTP) is less severe
following A2AR deletion (but see discussion below), and thus point to
the potential for A2AR antagonists as a therapeutic strategy for CNS
disorders characterized by high levels of brain inﬂammation.
Using the MCAO brain ischemia model, selective deletion of A2ARs
on BMDCs were clearly shown to attenuate transient MCAO-induced
brain infarct volume 22 hours post-reperfusion, an effect that was
associated with a reduction in the expression of several pro-
inﬂammatory cytokines [212]. A similar anti-inﬂammatory proﬁle in
gb-A2AR KOmice was observed following TBI [258]. Interestingly, the
duration of elevated inﬂammatory cytokines (TNF-α and IL-1β) was
apparently shorter (peak at 12 h) in the KO mice than that in the
wildtype group (peak at 24 h) following TBI, thereby revealing the
complex and dynamic nature of A2AR-regulation of TBI-induced pro-
inﬂammatory cytokines in brain. Lastly, an anti-inﬂammatory effect of
A2AR blockade has also been demonstrated in the MPTP-PD model
[138]. This effect was attributed to A2ARs on microglial cells since fb-
A2AR KO failed to alter acute MPTP neurotoxicity or inﬂammatory
status, but intracerebroventricular injection of KW-6002 in fb-A2AR
KO mice produced neuroprotection and attenuated MPTP-induced
striatal microglial and astroglial activation. The impact of A2AR
blockade on microglial activation was conﬁrmed by ﬂow cytometric
analysis demonstrating that A2AR antagonism largely attenuated the
progression of microglial cells to a fully activated state. It is interesting
to note that the broad spectrum of anti-inﬂammatory effects from
A2AR inactivation in brain is apparently at odds with the prominent
anti-inﬂammatory effect of A2AR activation in peripheral organs
[119,265,266]. To reconcile this difference, Dai et al. recently
demonstrated in microglial primary cell cultures following treatment
with lipopolysaccharide and in intact animals following TBI that
extra-synaptic glutamate levels can direct the switch of A2AR-
mediated responses from an anti-inﬂammatory and neuroprotective
role to a pro-inﬂammatory and cytotoxic role [260]. Thus, the level of
glutamate released from neurons and glial cells in response to brain
insults may dictate A2ARs’modulation of neuroinﬂammation in brain,
which is distinct from their modulation in peripheral tissues.
Together, these results suggest an important role for A2ARs in
regulating neuroinﬂammation and consequent brain injury. The
ﬁnding that glutamate critically controls the direction of A2ARs’
modulation of neuroinﬂammation reveals a novel mechanism for
neuronal control of inﬂammation through regulation of extra-
synaptic glutamate to modify A2ARs’ functional effects in brain.
3.2.3. Pain
Nociception involves both peripheral and central structures and
mechanisms and is another important adenosine-regulated neural
function. Evidence suggests a role for A1Rs, A2ARs, and A3Rs in pain
regulation.
A1Rs are abundant in mouse spinal cord, with the highest levels in
the outer lamina of the dorsal horns [74]. Therefore, most attention
has been devoted to pain pathways involving A1Rs, which have beenwell documented in a wide range of animal models including both
acute nociceptive tests and models of neuropathic and inﬂammatory
pain [267]. Previous work in which A1R agonists were administered
intrathecally pointed to A1R-mediation of analgesia [121]. Genetic
A1R knockout models later conﬁrmed the anti-nociceptive effects of
central A1Rs and suggested that A1Rs might represent new targets for
anti-nociceptive drug development since gb-A1R KO mice exhibited a
faster reaction to thermal pain than did wildtype mice [74].
Unlike A1Rs which are concentrated in anatomic regions relevant
for pain, A2ARs are found at low levels in pain-relevant areas such as
somatosensory cortex as well as dorsal spinal cord and dorsal root
ganglia. Nonetheless, it has been proposed that A2ARs in the CNS,
perhaps located on pre-synaptic inhibitory terminals of descending
ﬁbers in spinal cord, may modulate pain [268]. Previous pharmaco-
logic studies have shown that both A2AR agonists [269,270] and A2AR
antagonists [271] produce anti-nociception in different pain tests.
Tests in gb-A2AR KO mice have helped clarify these mixed results,
showing a hypoanalgesic effect in thermal tests of pain [80]. This
initial observation was later conﬁrmed and extended to the tail
immersion test, hot-plate test, and intraplantar formalin injection
paradigm [100,272,273]. Thus, studies using gb-A2AR KO mice
conﬁrm that A2AR blockade may possess some therapeutic potential
in alleviating certain pain states.
A3R KO mice also showed decreased sensitivity only to some
painful stimuli as assessed by the increase in latency in the hot plate
test [195], but no difference was detected between A3R KO and
wildtype mice in the nociceptive response to painful stimuli in the
tail-ﬂick test [195] or in response to mechanical or radiant heat
stimuli [274]. Hence, the exact role of A3R in modulation of various
painful stimuli remains to be determined.
3.2.4. Epilepsy
Extracellular adenosine is a critical determinant of the brain's
susceptibility to seizure activity [275]. This notion is recently
supported by transgenic studies where over-expression (140% of
normal) of ADK to reduce extracellular adenosine levels increased
susceptibility to status epilepsy while reduced expression (60% of
normal) offered resistance to status epilepsy [276]. Since astrogliosis
is a pathologic hallmark of the epileptic brain and contributes to
seizure generation through a variety of mechanisms [277–279], and
since ADK is induced in astrocytes following status epilepsy, this
ﬁnding provides a molecular link between astrogliosis and neuronal
dysfunction in epilepsy [276].
Adenosine's effect on epilepsy is largely mediated by A1Rs since
their activation reduces susceptibility to epilepsy and seizure-induced
excitotoxicity while their blockade produces the opposite effect [280].
A1Rs' critical role in the development of epilepsy is validated by the
demonstration of increased susceptibility to epilepsy after kainate
treatment [281] or mild cortical control impact [264,282] in gb-A1R
KO mice compared to wildtype mice. Studies with transgenic models
of AR/kinase have thus conﬁrmed the critical gating effect of
adenosine, largely acting at A1Rs, in the development of epilepsy.
Currently, adenosine delivery into epileptic brain regions is postulated
as a potential treatment strategy [283].
While A1Rs play a critical role in controlling epilepsy development,
the possible role of A2ARs in seizure development is less clear.
Pharmacologic studies suggest that A2AR activation can either suppress
[284,285] or promote seizures [286,287]. Genetic knockout studies
indicate that gb-A2AR KO mice are somewhat resistant to seizure
induced by ethanol withdrawal [288] and kindled seizures induced by
PTZ [289]. Additional experiments are needed to clarify the exact nature
of A2AR's involvement in controlling seizure development.
3.2.5. Drugs of abuse: addiction and withdrawal
The ventral striatum or nucleus accumbens is widely regarded as
the brain's reward center and the link between the brain's limbic and
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of abuse including cocaine, amphetamine, opiates, and ethanol has
been linked to this brain region [291]. The A2AR is the most
prominent AR subtype in ventral striatum where it is known to
interact closely with dopaminergic and glutamatergic pathways, two
neurotransmitter systems that are now generally recognized to
contribute to drug addiction and reward [291–293]. Consequently,
the majority of literature, particularly in studies with knockout mice,
has largely described work pertaining only to A2AR effects. The
following sections therefore provide an overview of the contributions
of A2ARs to cocaine, amphetamine, opiate, and ethanol addiction as
understood from A2AR KO studies.
3.2.5.1. Cocaine and amphetamine. Genetic A2AR KO models have
linked A2ARs to some of the maladaptive responses to the indirect
dopamine agonist cocaine and the dopamine releaser amphetamine,
thus leading to the suggestion that A2AR antagonists might be
employed to treat drug addiction. The rate of self-administration of
cocaine, motivation for cocaine (i.e., reduced breakpoint), and efﬁcacy
of its reinforcing effects (i.e., vertical shift in dose-response curve)
were all reduced in gb-A2AR KO mice compared to wildtype mice
[294]. Locomotor sensitization and conditioned place preference, in
contrast, remained undisturbed. In addition to cocaine, A2AR KOmice
have also consistently shown attenuated responses to amphetamine.
Both gb-A2AR KO and fb-A2AR KO mice failed to develop sensitized
locomotor responses to daily amphetamine [86,295], and in gb-A2AR
KO mice, this effect was associated with a lack of amphetamine-
induced striatal dynorphin mRNA expression [295]. Together these
ﬁndings point to an important role for A2ARs in the addictive
properties of cocaine and amphetamine.
3.2.5.2. Opiates (e.g., morphine). Adenosine may act at receptor targets
in different brain regions to modulate several actions of opiods
including opiod dependence. Several lines of pharmacologic evidence
support this notion, but are limited by the partial speciﬁcity of drugs.
Multiple studies examining the reward, motivational, and withdrawal
responses to morphine have been performed in gb-A2AR KOmice and
suggest that A2ARs are important modulators of the rewarding and
motivational properties of morphine. Gb-A2AR KO completelyFig. 1. Controversial role of adenosine receptors in different physiologic andabolished the acute rewarding effects of morphine [296,297] and
the aversive effects of morphine withdrawal [297]. These phenotypes
were accompanied by a reduction in morphine self-administration
and breakpoint compared to wildtype mice, suggesting that gb-A2AR
KO mice were less motivated, possibly the result of morphine's
reduced rewarding effects in the KO mice [296]. Gb-A2AR KO mice
also failed to develop tolerance to chronic morphine in this study
despite responding normally to acute morphine administration and
despite demonstrating comparable locomotor sensitization to mor-
phine relative to wildtype mice [296]. It should be noted, however,
that several studies have observed enhanced withdrawal signs in gb-
A2AR KO mice [100,298]. This enhancement was associated with the
functional activation status of μ-receptor-stimulated [35S]GTPγS
binding in nucleus accumbens [298]. Together, these data highlight
that A2AR antagonism might represent a therapeutic strategy for
treating or preventing drug addiction.
3.2.5.3. Ethanol. Adenosine may also modulate responses to ethanol.
Genetic A2AR KO studies provide some evidence that A2ARs are
important for mediating some behavioral effects of ethanol, although
these phenotypes were only observed in gb-A2AR KO mice generated
on a CD1 background and not on a C57BL/6 background. Gb-A2AR KO
mice from a CD1 background consumed more ethanol and were less
sensitive to the intoxicating effects (e.g., sedation, hypothermia) of
acute ethanol administration [299] as well as to its withdrawal [288].
Greater ethanol consumption among gb-A2AR KO mice was associated
with weakened rewarding properties of ethanol (i.e., reduced ethanol-
induced conditioned place preference) and heightened anxiolytic and
acute locomotor responses; no effects on ethanol-induced conditioned
taste aversion or locomotor sensitization were reported [193].
3.2.5.4. Summary. Evidence from genetic AR knockouts provides
compelling evidence for A2AR modulation of phenomena underlying
drug addiction. The broad inhibitory effect of A2AR knockout on the
development of locomotor sensitization to amphetamine suggests
that A2ARs may play a critical role in modulating dopaminergic
signaling, particularly when administered intermittently. A2AR
interaction with mGlu5Rs or CB1Rs might play a greater role.
Interestingly, it was reported that a synergy between D2Rs, CB1Rs,pathologic conditions and brain regions suggested by knockout studies.
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and enhances sensitivity to D2R signaling [300]. Deletion of A2ARs
might prevent this synergy and thus prevent the maladaptive cascade
that might lead to addiction and/or other disorders that might arise
from aberrant plasticity such as LID. Future studies might explore any
of these avenues in AR knockout mice.
4. Concluding remarks
Endogenous adenosine is a widely distributed upstream regulator
of a broad spectrum of neurotransmitters, receptors, and signaling
pathways that converge to contribute to the expression of an array ofTable 1
Controversial role of adenosine receptors suggested by knockout in different situations.
AR Effect revealed by AR KO
Physiologic Sleep/arousal A1 Promote sleep/inhibit arousal
A2A Promote sleep/inhibit arousal
Cognition A1 Anxiogenic
Increase aggression
A2A Improve spatial recognition memo
Improve working memory
Impair habit learning
Impair startle habituation and prep
Increase aggression
Spontaneous locomotion A2A Reduce locomotor activity (gb-A2A
No effect (fb-A2AR KO and st-A2A
Pathologic Ischemia/hypoxia A1 Reduce or exacerbate brain damag
A2A Reduce or exacerbate brain damag
A3 Reduce or exacerbate brain damag
Parkinson's disease (PD) A2A Neuroprotection
Increase locomotor activity
Huntington's disease (HD) A2A Reduce or exacerbate striatal dama
Traumatic brain injury (TBI) A2A Reduce brain damage
Epilepsy/Seizure A1 Lower threshold and promote epil
A2A Confer some resistance to seizures
Neuroinﬂammation A1 Enhance microgial response
A2A Inhibit or promote neuroinﬂamma
Pain A1 Antinociceptive
A2A Antinociceptive
A3 Antinociceptive or no effect
Drugs of abuse: addiction
and withdrawal
A2A Cocaine and morphine: reduce rewa
rate of self-administration
Amphetamine: reduce locomotor se
Ethanol: reduce reward, sensitivity
effects, withdrawalimportant and complex behaviors. Consequently, genetic knockout
analysis of adenosine and ARs reveal a broad spectrum of modulatory
effects on various normal and abnormal functions of the brain. These
functions range from neuronal plasticity, motor, motivation, sleep–
wake cycle, cognition, and emotion in the normal brain to neuropro-
tection, neuroinﬂammation, and maladaptive behavioral and neuro-
psychiatric disorders in the pathologic brain (Fig. 1 and Table 1).
Collectively, the ﬁndings from these studies emphasize the impor-
tance of broadly studying the phenotypes in AR knockout mice when
characterizing these knockout mouse lines. This ability of adenosine
to interact and integrate these critical brain processes is, for instance,
most evident in its modulation of cognitive functions, which usuallyBrain region References
Basal forebrain Bjorness et al., 2009 [77]
Hypothalamus Huang et al., 2005 [133]
Striatum
Cortex Johansson et al., 2001 [74]
Lang et al., 2003 [174]
Gimenez-Llort et al., 2002 [76]
ry Cortex Wang et al., 2006 [178]
Zhou et al., 2009 [179]
Striatum Yu et al., 2009 [180]
ulse inhibition Wang et al., 2003 [202]
Ledent et al., 1997 [80]
R KO) Striatum Chen et al., 1999 [81]
R KO) Chen et al., 2000 [85]
Bastia et al., 2005 [86]
Shen et al., 2008 [87]
e Cortex Johansson et al., 2001 [74]
Björklund et al., 2008 [204]
Turner et al., 2003 [207]
Olsson et al., 2004 [205]
e Cortex Chen et al., 1999 [81]
Yu et al., 2004 [212]
Aden et al., 2003 [137]
e Cortex Fedorova et al., 2003 [195]
Chen et al., 2006 [108]
Striatum Chen et al., 2001 [218]
Yu et al., 2008 [138]
Carta et al., 2009 [233]
ge Striatum Blum et al., 2003 [257]
Fink et al., 2004 [256]
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Cortex Li et al., 2009 [258]
Dai et al., 2010 [259]
epsy Cortex Fedele et al.2006 [281]
Hippocampus Haselkorn et al., 2010 [264]
Kochanek et al., 2006 [282]
Cortex El Yacoubi et al., 2001 [288]
El Yacoubi et al., 2008 [289]
Cortex Tsutsui et al., 2004 [263]
Haselkom et al., 2010 [264]
tion Cortex Yu et al., 2004 [212]
Yu et al., 2008 [138]
Striatum Li et al., 2009 [258]
Dai et al., 2010 [259]
Spinal cord Johansson et al., 2001 [74]
Striatum Ledent et al., 1997 [80]
Somatosensory cortex Bailey et al., 2002 [272]
Spinal cord Berrendero et al., 2003 [100]
Hussey et al., 2007 [273]
Maybe in peripheral tissues Fedorova et al., 2003 [195]
Wu et al., 2002 [274]
rd, motivation, Striatum (nucleus accumbens) Soria et al., [294]
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transmitters. The development of genetic knockout mice with
targeted deletion of the A1R or A2AR subtypes has especially been
instrumental in providing several new insights into the nature of
cognitive modulation by adenosine and its receptors. Notably, A2AR
knockout models highlight the pro-cognitive potential of A2AR
blockade, particularly under circumstances in which the cognitive
load is greater, as in the case of working memory. Moreover, region-
speciﬁc manipulation of the A2AR in striatum has revealed a novel
role for this receptor in the formation of habitual behavior and the
control of psychomotor activity. Together, these main recent ﬁndings
extend the functions of the A2AR beyond motor control to modifying
cognitive performance under physiologic and possibly pathologic
conditions as well. These studies raise the exciting possibility that
A2ARs may represent a target for improving cognitive function under
physiologic and/or pathologic states.
AR knockouts have also provided in recent years new insights
regarding the role of the ubiquitous ligand and its receptor targets in
brain pathology. They conﬁrm the fundamental role of the adenosine
system as an endogenous defense mechanism through its “retalia-
tory” metabolite and neuromodulatory effects in response to a
variety of brain insults. The elevated extracellular adenosine in
injured brain, acting through multiple ARs, is commonly recognized
and now largely validated by genetic knockout models to produce an
overall neuroprotective effect. However, studies in knockout mice
lacking the A1R and/or A2AR gene have unveiled an increasingly
complex and injury context-dependent effect in brain pathology. For
example, while activation of A1Rs generally exerts a broad
neuroprotective proﬁle, activation of A2ARs may in fact contribute
to brain damage. Moreover, while a general neuroprotective effect of
A2AR antagonism has emerged against a broad spectrum of brain
insults ranging from ischemia to PD to TBI, both A2AR agonists and
antagonists have been shown to protect against striatal damage in
animal models of HD. Such a disease context-dependent effect of ARs
may thus yield different net outcomes depending on the brain
region, disease, and/or timing of the manipulation (e.g., drug or gene
knockout) and/or insult. These complex and even opposing pheno-
types may reﬂect the nature of adenosine's multi-level interactions
with a vast array of neurotransmitter and inﬂammatory/immune
systems. A prominent example of such a context-dependency of
adenosine's effects is the demonstration of the close interaction
between local glutamate levels and adenosine acting at A2ARs to
control neuroinﬂammation. Increased local levels of glutamate in
injured brain regions can switch the anti-inﬂammatory effect of
A2AR activation to that of a pro-inﬂammatory effect and conse-
quently promote brain damage. This ﬁnding unexpectedly revealed a
novel mechanism by which extra-synaptic glutamate, in addition to
its well-documented neuronal excitotoxic effects, can control
neuroinﬂammation via regulation of the A2AR during brain injury.
In summary, AR knockouts, particularly for the A1R and A2AR,
have provided signiﬁcant insight into adenosine's control of complex
physiologic and pathologic phenomena. These ﬁndings extend and
strengthen support of A2ARs and A1R in brain as targets for several
neurologic and psychiatric diseases. However, they also emphasize
the importance of considering the disease context-dependent effect
when developing AR-based therapeutic strategies and support the
notion that new developments of such drugs will likely need to be
speciﬁcally tailored to a given disease.References
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